Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01073397
Other study ID # IRB00009138
Secondary ID 1R21AT004234-01A
Status Completed
Phase N/A
First received
Last updated
Start date January 2010
Est. completion date May 2011

Study information

Verified date August 2018
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to compare yoga and health and wellness classes for helping perimenopausal or newly postmenopausal women who are experiencing hot flashes. The investigators want to learn about the effects of yoga and health and wellness classes on symptoms and other quality of life issues. The results of this study may provide important knowledge to women and clinicians who counsel women with menopausal hot flashes.


Description:

Hot flashes and/or night sweats are the most common and troubling symptoms associated with menopause. It is estimated that 64% to 87% of women report experiencing hot flashes for an average of about 4 years. For many women, these symptoms are frequent and severe enough to become debilitating and interfere with daily activities. They often occur at night, disturbing sleep and leading to daytime irritability, fatigue and depressed mood. About 30-40% of menopausal women seek medical help for hot flashes. Relief from hot flashes has been shown to be the primary reason that women initiate hormone therapy (HT).

HT is currently the gold standard for treatment of vasomotor symptoms. A Cochrane Database systematic review showed a 75% reduction in hot flash frequency with hormone therapy compared to placebo.1 However, recent findings from the Women's Health Initiative (WHI) trial indicate that benefits of HT are outweighed by risks, such as coronary heart disease, stroke, pulmonary embolism, breast cancer, and probable dementia. The wide publicity of the WHI results has heightened women's concerns about taking HT and many women have sought alternative treatments for hot flashes. These alternatives include other pharmaceutical agents, herbal or dietary remedies, and behavioral therapies. Unfortunately, many of these agents have a high incidence of side effects or have not been shown to be effective. A recent NIH conference has called for more research on alternative treatments for hot flashes.

Behavioral interventions involving relaxation and slow deep, abdominal breathing have been found to be useful for reducing mild- to moderate-intensity hot flashes. Although the physiological mechanisms for the effectiveness of these interventions are not completely understood, there is some suggestion that they may help reduce sympathetic activity which is related to the narrowing of the thermoneutral zone. It is currently thought that hot flashes are linked to a disruption in thermoregulation and that elevated levels of brain norepinephrine may be the primary mechanism for altered thermoregulation. Breathing techniques form the most integral core of any yoga practice which involves the combination of physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). Despite suggestions that yoga may be beneficial for the relief of hot flashes, these potential benefits have not been well-studied.

To date, treatment efficacy for hot flashes has been limited to self-reported, subjective symptoms. While subjective hot flashes are important from a woman's perspective in her decision-making with respect to treatment, research has shown that they can be influenced by mood and reporting biases. Objective measures are not subject to these biases and have the advantage of providing insight as to whether an intervention has a physiological effect. However, until recently, reliable objective measures that could be used in an ambulatory setting were not available. NCCAM has recently funded the development of new technologies to monitor objective hot flashes in an ambulatory setting, as measured by skin conductance. This technology greatly enhances our ability to fully evaluate the impact of treatment on both subjective and objective hot flashes.

The primary goal of this R21 pilot grant is to obtain preliminary data on the efficacy of Integral Yoga for reducing self-reported menopausal hot flashes. Secondary aims are to determine the impact of yoga on objective hot flashes and other outcomes and study feasibility. Our primary hypothesis will be a greater reduction in subjective hot flash frequency and severity in the yoga group than in two control groups. Secondary outcomes will include a greater reduction in objective hot flash frequency; a greater decrease in hot flash interference; and greater improvement in sleep, other symptoms, mood, perceived stress, and overall quality of life in the yoga group.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 45 Years to 58 Years
Eligibility Inclusion Criteria:

- At least 2 months since last menses

- Age 45-58 years

- Moderate to severe vasomotor symptoms for at least 4 weeks (at least 4/day on average)

- Self-reported general good health

- Adequate English to understand informed consent form, questionnaires, and converse with study staff

- Agree not to use pharmaceutical agents for treating hot flashes during the study

Exclusion Criteria:

- Hormone therapy use within 12 weeks prior to study screening, including systemic estrogen, progestin or androgen therapy

- Selective estrogen receptor modulator (Evista® and Novaldex®) or aromatase inhibitor use within 6 months

- Cancer at any time

- Untreated thyroid disease

- Initiation of herbal or nutritional supplements for hot flashes within the past 4 weeks

- Significant psychiatric disorder, including regular use of antidepressants or anxiolytics

- Regular use of clonidine or Bellergal® within the past 12 weeks

- Any past use of yoga for hot flashes

- Yoga or Acupuncture for any reason within the past 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Yoga
Integral Yoga class (90 minutes per class), Once weekly for 10 weeks

Locations

Country Name City State
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subjective Hot Flashes Subjective hot flashes measured by daily diaries Weekly
Secondary Objective hot flashes Objective hot flashes measured by skin conductance. 3 days
Secondary Hot flash interference This measure assesses the impact of hot flashes on daily activities and quality of life. 1 week
See also
  Status Clinical Trial Phase
Completed NCT04090957 - Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women Phase 3
Completed NCT01052454 - Mindfulness-Based Stress Reduction for Hot Flashes Phase 0
Completed NCT00535288 - Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013) Phase 3
Recruiting NCT00906308 - A Study of MF101 in Postmenopausal Women Phase 3
Completed NCT01452373 - Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women Phase 3
Completed NCT00560833 - Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012) Phase 3
Completed NCT05033886 - A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause Phase 3
Completed NCT05083884 - A Survey About Hot Flashes in Women Going Through the Menopause
Completed NCT01178892 - MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation N/A
Completed NCT00397176 - Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women Phase 1
Recruiting NCT06122181 - Study of HS-10384 in Participants of Chinese Postmenopausal Women Phase 1
Not yet recruiting NCT06393673 - A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women Phase 2
Withdrawn NCT02202707 - Vasomotor Symptoms and Cardiovascular Control N/A
Completed NCT00356447 - Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. Phase 3
Completed NCT05312567 - FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms Phase 2
Terminated NCT01353963 - Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients Phase 4
Completed NCT00446199 - Low-dose Hormone Therapy for Relief of Vasomotor Symptoms Phase 3
Completed NCT05850338 - Determination of the Effects of Autogenic Relaxation Exercise and Cold Pillow Application on Vasomotor Symptom Control and Quality of Life in Postmenopausal Women N/A
Completed NCT02803268 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms Phase 1
Completed NCT00683800 - Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women Phase 3